Filing Flows › Castle Biosciences (CSTL) › Guidance & outlook

Castle Biosciences (CSTL) guidance and outlook

Castle Biosciences (CSTL) raised its guidance on Nov 5, 2026: Revenue $385M–$395M for FY2026. Castle Biosciences' 10-Q filed Nov 5, 2026 makes 35 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• In a typical year, we estimate that approximately 130,000 patients are diagnosed with invasive CM in the U.S., representing an estimated U.S. total addressable market (“TAM”) of approximately $540 million.
• We estimate that approximately 50% of patients diagnosed with CM are 65 years of age or older.
• Using multiple data sources focused on one-year prevalence, we estimate that there are approximately 10 million individuals ages 12 and older in the U.S. with moderate-to-severe AD, representing an estimated U.S.
• Of the 2 million suspicious pigmented lesions biopsied annually in the U.S., we estimate that approximately 300,000 of those present a difficult-to-diagnose melanocytic lesion, representing an estimated U.S.
• We expect these assets to support the future development of TissueCypher and enable the potential incorporation of additional molecular modalities.
• For our AdvanceAD-Tx product line, we plan to continue expanding availability in a phased manner throughout the remainder of 2026.
• The extent of the impact of these factors on our operational performance and financial condition, including our ability to execute our business strategies and initiatives in the expected timeframe, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact our business.
• We expect our expenses will increase substantially over time as we:
• We believe there are several important factors that have impacted, and that we expect will continue to impact, our operating performance and results of operations, including:
• Under ASC 606, we recognize revenue at the amount we expect to be entitled, subject to a constraint for variable consideration, in the period in which our tests are delivered to the treating clinicians.
• Variable consideration for Medicare claims that are not covered by Medicare, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time.
• Our ability to increase our revenues will depend on our ability to further penetrate our target markets, and, in particular, generate sales through our direct sales force, maintain Medicare coverage for our currently marketed products, develop and commercialize additional tests, including through acquisitions, obtain reimbursement from additional third-party payors and increase our reimbursement rate for tests…

Castle Biosciences' latest quarter

Questions

Did Castle Biosciences raise or lower its guidance?

Castle Biosciences (CSTL) raised its guidance on Nov 5, 2026: Revenue $385M–$395M for FY2026.

What does Castle Biosciences expect?

In a typical year, we estimate that approximately 130,000 patients are diagnosed with invasive CM in the U.S., representing an estimated U.S. total addressable market (“TAM”) of approximately $540 million. We estimate that approximately 50% of patients diagnosed with CM are 65 years of age or older. Using multiple data sources focused on one-year prevalence, we estimate that there are approximately 10 million individuals ages 12 and older in the U.S. with moderate-to-severe AD, representing an estimated U.S.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.